Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#3636 Texture analysis in the prediction of progression-free survival (PFS) in patients with progressive neuroendocrine tumors (NETs) treated with lanreotide autogel (LAN) in the prospective, open-label, non-comparative, phase 2 CLARINET FORTE trial

Introduction: Tumor texture analysis may provide new imaging biomarkers for PFS prediction in patients with NETs.

Conference:

Presenting Author:

Authors: Dromain C, Truong Thanh X, Grandoulier A, Pavel M,

Keywords: texture analysis, progression-free survival, neuroendocrine tumor,

#3489 Texture analysis of liver NET liver metastases on Ga-68 DOTATATE PET candidate to PRRT: Non-invasive histological and prognostic stratification

Introduction: Liver metastases (LM) from well-differentiated (G1/2) neuro-endocrine tumor (NET) can be managed by peptide-receptor radiotherapy (PRRT). Grading determination requires a biopsy; however, biological features can be heterogenous across metastases. Moreover, time-to-progression (TTP) after PRRT can be widely variable.

Conference:

Presenting Author: Fiz F

Authors: Fiz F, Centurioni G, La Fougère C,

Keywords: PRRT, Radiomics, Texture Analysis, PET, PET/CT,

#3439 Role of Radiomics in the Everolimus response prediction of metastatic neuroendocrine tumors

Introduction: Radiomics was shown to provide non-invasive imaging biomarkers predicting prognosis and treatment response.

Conference:

Presenting Author: Magi L

Authors: Magi L, Polici M, Zerunian M, Rinzivillo M, Marasco M,

Keywords: response to treatment, Everolimus, neuroendocrine tumor, Radiomics, targeted therapy,